Resistance to antiplatelet therapy

被引：44

作者：

Guthikonda S. ^{[1
]}

Lev E.I. ^{[1
]}

Kleiman N.S. ^{[1
]}

机构：

[1] Baylor College of Medicine, Houston, TX 77030

来源：

Current Cardiology Reports | 2005年 / 7卷 / 4期

关键词：

Aspirin; Clopidogrel; Arterioscler Thromb Vasc Biol; Aspirin Resistance; Indobufen;

D O I：

10.1007/s11886-005-0044-0

中图分类号：

学科分类号：

摘要：

Cardiovascular mortality continues to be high and events continue to occur in patients taking antiplatelet medications. Aspirin and clopidogrel have become integral parts of management in patients with coronary artery disease and after percutaneous angioplasty. However, the platelet responses to aspirin and clopidogrel are not uniform. Diminished or lack of response to these agents has been termed aspirin resistance and clopidogrel resistance. These phenomena have tremendous clinical significance as together they may occur in more than 50% of all patients on chronic therapy with aspirin or clopidogrel. Postulated mechanisms of aspirin and clopidogrel resistance include alterations in genetic, pharmacokinetic, and platelet properties. There is a dearth of information in regard to their clinical significance, methods to test them, and strategies to treat them. Further research is necessary in these areas to identify these patients and treat them appropriately. Copyright © 2005 by Current Science Inc.

引用

页码：242 / 248

页数：6

共 52 条

[1]

Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, BMJ, 308, pp. 81-106, (1994)

[2]

Yusuf S., Zhao F., Mehta S.R., Et al., Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N. Engl. J. Med., 345, pp. 494-502, (2001)

[3]

Gum P.A., Kottke-Marchant K., Welsh P.A., Et al., A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease, J. Am. Coll. Cardiol., 41, pp. 961-965, (2003)

[4]

Matetzky S., Shenkman B., Guetta V., Et al., Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, pp. 3171-3175, (2004)

[5]

Cattaneo M., Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance, Arterioscler Thromb. Vasc. Biol., 24, pp. 1-8, (2004)

[6]

Chen W.H., Lee P.Y., Ng W., Et al., Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pre-treatment, J. Am. Coll. Cardiol., 43, pp. 1122-1126, (2004)

[7]

Wang J.C., Aucoin-Barry D., Manuelian D., Et al., Incidence of aspirin nonresponsiveness using the ultegra rapid platelet function assay-ASA, Am. J. Cardiol., 92, pp. 1492-1494, (2003)

[8]

Chakroun T., Gerotziafas G., Robert F., Et al., In vitro aspirin resistance detected by PFA-100™ closure time: Pivotal role of plasma von Willebrand factor, Br. J. Haematol., 124, pp. 80-85, (2004)

[9]

Andersen K., Hurlen M., Arnesen H., Seljeflot I., Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease, Thromb. Res., 108, pp. 37-42, (2003)

[10]

Grundmann K., Jaschonek K., Kleine B., Et al., Aspirin non-responders status in patients with recurrent cerebral ischemic attacks, J. Neurol., 250, pp. 63-66, (2003)

← 1 2 3 4 5 6 →